Deirdre Eschler is an Endocrinology/Metabolic physician affiliated with Stony Brook Medicine. OpenAlex indexes 13 publications with 361 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Stony Brook Internist
Ufpc Smumc, Hsc Level 15, Rm 60
Stony Brook, NY 117948154
Telephone
631-444-1665Registry record last updated 30 Apr 2014.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20251 payment
- Ascendis Pharma Endocrinology IncProgram year20251 payment
- Insulet CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.2%GLP-1 receptor agonist17%Ozempic57%Mounjaro43%Part D≥26 patientsInsulin Analog14.1%Lantus Solostar53%Novolog Flexpen15%Humalog Kwikpen U-10014%Humalog10%Novolog8%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
32.6%l-Thyroxine25%Levothyroxine Sodium81%Synthroid19%Part D≥65 patientsThyroid Hormone Synthesis Inhibitor4.3%Methimazole100%Part D≥11 patients+ 2 more classes in this area
Cardiovascular
7%Statin7%Atorvastatin Calcium62%Rosuvastatin Calcium38%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- How I Treat a Patient with Primary Aldosteronism
Clinical Journal of the American Society of Nephrology
2026 - LBSUN288 Improved Glycemic Control Following Oophorectomy In A Post-menopausal Woman With Ovarian Hyperthecosis
Journal of the Endocrine Society
2022 - Acute Sensorineural Hearing Loss - an Unusual Presentation of Uncontrolled DM
Journal of the Endocrine Society
2021 - Intravenous Insulin Resistance in a Critically Ill Patient Secondary to Decreased Peripheral Perfusion
Journal of the Endocrine Society
2021 - Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature
AACE Clinical Case Reports
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Gerald Smaldone, MD, PhD
Stony Brook Medicine
Eric Rashba, MD
Stony Brook Medicine
Nand Wadhwa, MD
Stony Brook Medicine
Steven Weissbart
Stony Brook Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”